Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer

Phase 1/2 Completed 39 enrolled University of Louisville James Graham Brown Cancer Center · collab

NaSingle-groupOpen-labelTreatment

Summary

This clinical research study is being done because there is no effective treatment for advanced androgen-independent prostate cancer. This study will determine if the combination of medications (Taxotere and Doxil) are effective in this kind of cancer.

Timeline

Start: 2004-01
Primary completion: 2010-08
Completion: 2010-08

Publications

Laber DA, Eatrides J, Jaglal MV, Haider M, Visweshwar N, Patel A. A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer. Med Oncol. 2020 Sep 26;37(10):95. doi: 10.1007/s12032-020-01420-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	25 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	30 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	25 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	30 mg/m2	Intravenous

Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications